Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c, provides guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $1.26, $0.11 better than the analyst estimate of $1.15. Revenue for the quarter came in at $298 million versus the consensus estimate of $294.15 million.

GUIDANCE:

Halozyme Therapeutics sees FY2025 EPS of $4.95-$5.35, versus the consensus of $5.05. Halozyme Therapeutics sees FY2025 revenue of $1.15-1.225 billion, versus the consensus of $1.184 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance